Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase a broad range of integrated oncology solutions, including IntelliSpace Genomics and IntelliSpace Oncology, to help support and scale precision medicine programs to assist oncologists with treatment decisions at the 2018 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago, Ill.
Individualized, precision medicine is key in reaching accurate diagnoses and effective treatment plans for cancer patients, but should be informed through accepted best practices to maximize quality of care and outcomes. These patients require constant vigilance and collaboration across multiple domains, and oncologists can face challenges when trying to compile a complete picture of all necessary patient information to support the decision making process. With new technologies and solutions like IntelliSpace Oncology, a cloud-based platform integrating information across different clinical domains such as radiology, pathology, EHR systems and genomics, all key patient data is seamlessly incorporated into one location, to provide a clear, intuitive view of patient status in its disease and state context that facilitates data-driven clinical decision support.
“Philips is committed to empowering clinicians with successful oncology care pathways by providing them with the necessary solutions to do so,” said Louis Culot, general manager, Oncology Informatics, Philips. “As a leader in oncology diagnostics, informatics and therapeutics, Philips is always striving to find ways to make life better for those suffering from cancer, as well as those responsible for delivering that care.”
As a leader in oncology diagnostics, informatics and therapeutics, Philips is always striving to find ways to make life better for those suffering from cancer, as well as those responsible for delivering that care.
Louis Culot
General manager, Oncology Informatics, Philips
At ASCO18, Philips will spotlight specific, end-to-end oncology solutions to empower data-driven clinical decision support driving clinical, operational and financial benefits across the following key areas:
Integrative Diagnostics:
Deeper Insights:
Confident path:
During ASCO 2017, Philips announced it had signed an agreement with Memorial Sloan Kettering Cancer center to develop new methodologies and informatics approaches for advanced precision diagnostics to help uncover the drivers for cancer at the single-cell level. In 2018, Philips has signed additional agreements with Dana-Farber and Perlmutter Cancer Center at NYU Langone Health.
For more information on the full portfolio of Philips integrated oncology solutions and Philips’ presence at the American Society of Clinical Oncology Annual Meeting, visit Booth #7159 on the exhibit floor, and follow @PhilipsLiveFrom for #ASCO18 updates throughout the event.
References
[2] OncoSignal is available for Research Use Only and not for use in Diagnostic Procedures (not for use in clinical settings).
[3] TissueMark is not intended for diagnostic, monitoring or therapeutic purpose or in any other manner for regular medical practice.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
